These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 17437439

  • 1. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
    Figg WD, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P, Wright JJ, Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E, Chen C, Dahut W.
    BJU Int; 2007 May; 99(5):1047-55. PubMed ID: 17437439
    [Abstract] [Full Text] [Related]

  • 2. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, Bamias A.
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [Abstract] [Full Text] [Related]

  • 3. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
    Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD.
    J Clin Oncol; 2004 Jul 01; 22(13):2532-9. PubMed ID: 15226321
    [Abstract] [Full Text] [Related]

  • 4. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
    Oudard S, Legrier ME, Boyé K, Bras-Gonçalves R, De Pinieux G, De Cremoux P, Poupon MF.
    J Urol; 2003 May 01; 169(5):1729-34. PubMed ID: 12686819
    [Abstract] [Full Text] [Related]

  • 5. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer.
    Sella A, Sternberg CN, Skoneczna I, Kovel S.
    BJU Int; 2008 Dec 01; 102(11):1607-9. PubMed ID: 18990177
    [Abstract] [Full Text] [Related]

  • 6. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer.
    Mathew P, Logothetis CJ, Dieringer PY, Chen I, Pagliaro LC, Bekele BN, Zhou X, Daliani DD.
    Clin Genitourin Cancer; 2006 Sep 01; 5(2):144-9. PubMed ID: 17026803
    [Abstract] [Full Text] [Related]

  • 7. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
    Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED.
    N Engl J Med; 2004 Oct 07; 351(15):1513-20. PubMed ID: 15470214
    [Abstract] [Full Text] [Related]

  • 8. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM.
    J Clin Oncol; 2005 May 20; 23(15):3343-51. PubMed ID: 15738542
    [Abstract] [Full Text] [Related]

  • 9. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Meluch AA, Spigel DR, Yost K, Meng C, Greco FA.
    Clin Genitourin Cancer; 2006 Mar 20; 4(4):287-92. PubMed ID: 16729913
    [Abstract] [Full Text] [Related]

  • 10. Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience.
    Bamias A, Bozas G, Antoniou N, Poulias I, Katsifotis H, Skolarikos A, Mitropoulos D, Alamanis C, Alivizatos G, Deliveliotis H, Dimopoulos MA.
    Eur Urol; 2008 Feb 20; 53(2):323-31. PubMed ID: 17445976
    [Abstract] [Full Text] [Related]

  • 11. Future directions in the treatment of androgen-independent prostate cancer.
    Petrylak DP.
    Urology; 2005 Jun 20; 65(6 Suppl):8-12. PubMed ID: 15939077
    [Abstract] [Full Text] [Related]

  • 12. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
    Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA.
    Cancer; 2002 Mar 01; 94(5):1457-65. PubMed ID: 11920502
    [Abstract] [Full Text] [Related]

  • 13. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
    Pectasides D, Pectasides E, Papaxoinis G, Koumarianou A, Psyrri A, Xiros N, Tountas N, Kamposioras K, Papatsibas G, Floros T, Gouveris P, Karageorgopoulou S, Economopoulos T.
    Anticancer Res; 2009 Feb 01; 29(2):769-75. PubMed ID: 19331234
    [Abstract] [Full Text] [Related]

  • 14. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
    Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW.
    Clin Cancer Res; 2005 Jan 01; 11(1):284-9. PubMed ID: 15671557
    [Abstract] [Full Text] [Related]

  • 15. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    Nelius T, Klatte T, Yap R, Kalinski T, Röpke A, Filleur S, Allhoff EP.
    BJU Int; 2006 Sep 01; 98(3):580-5. PubMed ID: 16925757
    [Abstract] [Full Text] [Related]

  • 16. Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.
    Sella A, Sternberg C, Kovel S, Yarom N, Skoneczna I.
    BJU Int; 2007 Sep 01; 100(3):533-5. PubMed ID: 17559560
    [Abstract] [Full Text] [Related]

  • 17. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.
    Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ.
    Clin Genitourin Cancer; 2007 Jun 01; 5(5):323-8. PubMed ID: 17645829
    [Abstract] [Full Text] [Related]

  • 18. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis.
    Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, Johnson CS, Scott-Horton TJ, Li L, McLeod HL, Sweeney CJ.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6094-9. PubMed ID: 17062685
    [Abstract] [Full Text] [Related]

  • 19. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.
    Petrylak DP, Macarthur RB, O'Connor J, Shelton G, Judge T, Balog J, Pfaff C, Bagiella E, Heitjan D, Fine R, Zuech N, Sawczuk I, Benson M, Olsson CA.
    J Clin Oncol; 1999 Mar 15; 17(3):958-67. PubMed ID: 10071290
    [Abstract] [Full Text] [Related]

  • 20. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
    Dawson NA, Halabi S, Ou SS, Biggs DD, Kessinger A, Vogelzang N, Clamon GH, Nanus DM, Kelly WK, Small EJ, Cancer And Leukemia Group B.
    Clin Genitourin Cancer; 2008 Sep 15; 6(2):110-6. PubMed ID: 18824434
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.